Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Immunogenicity and Lot Comparability of DAPTACEL™ (Aventis Pasteur Classic Five-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) When Administered With Other Recommended Vaccines at 2, 4, 6, and 15 to 16 Months of Age.

NCT00662870 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00662870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00662870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Immunogenicity and Lot Comparability of DAPTACEL™ (Aventis Pasteur Classic Five-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) When Administered With Other Recommended Vaccines at 2, 4, 6, and 15 to 16 Months of Age.
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2001
Completion date
January 31, 2004
Enrollment
1,941 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b, polio, tetanus, whooping cough